PPD Neuroscience Research

Neuroscience Clinical Research

Partnering to achieve your next neuroscience breakthrough

Navigating the complexities of neuroscience research and clinical trials requires partnership with an experienced, global CRO equipped to handle challenges and drive solutions forward.

Unmet patient needs outweigh the available treatment solutions for many conditions that affect the central nervous system (CNS). Every breakthrough can impact how neurological disorders are managed and treated—potentially reshaping the futures of patients and their caregivers.

Advancing your treatment requires well-staffed sites equipped for and experienced in neuroscience. PPD is prepared to connect you with a large selection of appropriate sites and will help establish streamlined, simple study designs to increase the likelihood of successful site selection.

Your commitment to developing meaningful solutions to neuroscientific health challenges is shared by PPD experts. From supporting patients and sites with simple, accessible decentralized trial solutions to providing proven placebo response mitigation, our end-to-end services transform uncertainties into actionable information that furthers research and therapeutics. And the patient is at the center of everything we do. Our patient concierge services reduce individual burden and increase access to clinical trials for those who need them most.

Preparing for growth in neurodegenerative treatment opportunities

Advances in the understanding of neurology have led to significant progress in the development of treatments for neurodegenerative disorders. While patient enrollment and retention for clinical trials in this field can be challenging, CROs with the right expertise, tools and passion can enable sponsors to implement successful, cost-effective studies that minimize site and patient burden.

See how innovative thinking makes it possible for PPD to enable you to bring your breakthrough therapies for neurodegenerative diseases to market as quickly, safely and cost-effectively as possible.

Access the article